or Try an Advanced Search...

    Induced Stem Cells Stocks List

    Symbol Grade Name % Change
    TNYA D Tenaya Therapeutics, Inc. -2.70
    BCLI F Brainstorm Cell Therapeutics Inc. 2.38
    LYEL F Lyell Immunopharma, Inc. -11.01
    CARM F Carisma Therapeutics, Inc. -1.69
    FATE F Fate Therapeutics, Inc. -4.73
    IPSC F Century Therapeutics, Inc. -1.59
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biology Biotechnology Life Sciences Stem Cell Adult Stem Cell Biopharmaceutical Cancer Cell Biology Cell Therapy Cloning Solid Tumors Amyotrophic Lateral Sclerosis Antigen Biomarkers Blood Cells Bone Bone Marrow Cancer Care Cell Encapsulation Cell Product

    Related ETFs - A few ETFs which own one or more of the above listed Induced Stem Cells stocks.

    Symbol Grade Name Weight
    CNCR F Loncar Cancer Immunotherapy ETF 2.22
    WDNA D WisdomTree BioRevolution Fund 1.09
    HRTS F Tema Cardiovascular and Metabolic ETF 0.43
    BBC F Virtus LifeSci Biotech Clinical Trials ETF 0.37
    GNOM F Global X Genomics & Biotechnology ETF 0.31
    View all Induced Stem Cells ETFs...
    Compare ETFs
    Compare BBC to GNOM Compare CNCR to BBC Compare WDNA to HRTS

        Induced Stem Cells Stocks Recent News

        Date Stock Title
        Nov 20 FATE Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options
        Nov 19 TNYA Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
        Nov 19 FATE Wall Street Breakfast Podcast: Fate Therapeutics Rises On Lupus Drug Data
        Nov 18 FATE Fate Therapeutics Shares Rise After 'Promising' Lupus Treatment Results
        Nov 18 FATE Fate stock rallies 37% on positive Phase 1 data for FT819, FT522
        Nov 18 FATE Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
        Nov 18 FATE Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
        Nov 17 CARM Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024
        Nov 15 FATE Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
        Related Industries: Biotechnology
        Related Stock Lists: Biology Biotechnology Life Sciences Stem Cell Adult Stem Cell Biopharmaceutical Cancer Cell Biology Cell Therapy Cloning Solid Tumors Amyotrophic Lateral Sclerosis Antigen Biomarkers Blood Cells Bone Bone Marrow Cancer Care Cell Encapsulation Cell Product
        Induced Stem Cells

        Induced stem cells (iSCs) are stem cells that have been artificially created from adult cells, such as skin cells, by using genetic reprogramming techniques. These cells have the potential to become any type of cell in the body, and can be used to study diseases, develop treatments, and even create replacement tissues and organs.

        Browse All Tags